A recent retrospective study published in the Indian Journal of Dermatology in September 2026 reveals that the targeted monoclonal antibody ixekizumab achieves a rapid 90.9% reduction in...
This is a summary. For the full story, refer to the original source. Public of India presents verified citizen-relevant reporting.